Abstract Amyloid plaques are composed primarily of amyloid-beta (Ab) peptides derived from proteolytic cleavage of amyloid precursor protein (APP) and are considered to play a pivotal role in Alzheimer's disease (AD) pathogenesis. Presently, AD is diagnosed after the onset of clinical manifestations. With the arrival of novel therapeutic agents for treatment of AD, there is an urgent need for biomarkers to detect early stages of AD. Measurement of plasma Ab has been suggested as an inexpensive and non-invasive tool to diagnose AD and to monitor Ab modifying therapies. However, the majority of cross-sectional studies on plasma Ab levels in humans have not shown differences between individuals with AD compared to controls. Similarly, crosssectional studies of mouse plasma Ab have yielded inconsistent trends in different mouse models. However, longitudinal studies appear to be more promising in humans.
Introduction
The pathological hallmarks of Alzheimer's disease (AD) are amyloid plaques, neurofibrillary tangles, synaptic degeneration, and neuronal loss (Price and Sisodia 1998) . Amyloid plaques are composed of amyloid-beta (Ab) 42 and 40 peptides derived from the proteolytic cleavage of amyloid precursor protein (APP) by b-site APP cleavage enzyme 1 (BACE1) (Sinha et al. 1999; Vassar et al. 1999) and the c-secretase (De Strooper 2003) . The endosome and the endocytic pathway have been proposed as possible sites for the b and c cleavage of APP (Small and Gandy 2006) , and the resulting Ab peptides are secreted by both neuronal and non-neuronal cells (Selkoe 1997 (Selkoe , 2002 . Recently, soluble forms of Ab have been implicated in neurotoxicity (Lambert et al. 1998; Walsh et al. 2002; Lesne et al. 2006) , and may correlate better with cognition than amyloid plaque burden (Lue et al. 1999; McLean et al. 1999) .
The clinical manifestations of AD, i.e. cognitive decline and neuro-behavioral changes, are preceded by a long preclinical stage characterized by the silent development of neuropathological lesions (Crystal et al. 1988; Katzman et al. 1988; Troncoso et al. 1996; Price and Morris 1999; Schmitt et al. 2000; Morris and Price 2001) . These preclinical and early stages of AD represent the ideal time to treat the disease (Neugroschl and Davis 2002) with newly emerging approaches such as gamma-secretase inhibitors (Siemers et al. 2006 (Siemers et al. , 2007 or immunotherapy (Hock et al. 2003) .
As Ab is considered to play an early and pivotal role in AD pathogenesis (Hardy and Selkoe 2002) , it may be a useful tool in diagnosing AD in the preclinical/early stages, as well as for monitoring potential Ab modifying therapies (Galasko 2005) . While human CSF Ab levels have mostly shown reduction with disease progression (Jensen et al. 1999) , much of the data on plasma Ab levels have been equivocal (Irizarry 2004) . However, since plasma Ab would be less invasive and more accessible than CSF Ab as a biomarker, many strategies are under investigation to optimize plasma Ab as a predictor of AD as well as to monitor the efficacy of Ab modifying agents.
In this article, we will review studies involving plasma Ab levels in humans as well as in transgenic (tg) mouse models of AD. Further, we will discuss the challenges that arise in measuring plasma Ab levels as well as ways to optimize the detection of Ab in plasma.
Plasma Ab Levels

Human
While the data on human cerebrospinal fluid (CSF) mostly show decreased Ab levels correlating with diagnosis and disease progression of AD (Jensen et al. 1999; Sunderland et al. 2003) , much of the data on human plasma Ab remain unclear. Studies have shown that subjects who exhibit overproduction of Ab such as individuals with familial forms of AD and Down's syndrome have higher plasma Ab levels compared to controls (Scheuner et al. 1996; Tokuda et al. 1997; Iwatsubo 1998) . However, only 5-10% of the AD cases are familial (Goate et al. 1991; Levy-Lahad et al. 1995; Sherrington et al. 1995) and the remaining cases are mostly sporadic (sAD) and late-onset AD (LOAD). While Ab production is thought to be increased in FAD (Selkoe 2001) , sAD is thought to be caused by the imbalance between Ab production and clearance (Selkoe 2001; Hardy and Selkoe 2002) . Many of the cross-sectional studies examining sAD subjects have not shown significant difference in the plasma Ab levels compared to cognitively normal controls or controls with other neurological diseases (Table 1) .
There may be several reasons why the data on plasma Ab levels in sAD subjects are less consistent compared to CSF Ab levels. Direct communication between the brain interstitial fluid (ISF) and CSF (Silverberg et al. 2003) may allow the Ab level in the brain ISF to be closely reflected in the CSF. It is thought that decreasing CSF Ab levels with progression of AD is a reflection of increasing Ab deposition into insoluble plaques in the brain, as well as decreasing numbers of neurons that are able to produce Ab in the brain (Jensen et al. 1999) . In plasma, interpretation of the Ab level is more complex. In addition to variability found with age and disease severity (Giedraitis et al. 2007) , there are other factors that come into play. One of the factors is the origin of Ab in the plasma. There is evidence to suggest that most of the Ab production occurs in the brain (Laird et al. 2005) , however, the possibility of Ab derived from other sources must be considered. Proteolytic processing of APP by BACE1 leads to the formation of Ab. BACE1 activity can be found at very high levels in the AD brain (Holsinger et al. 2002; Yang et al. 2003) , but is also present at lower levels in peripheral organs such as skeletal muscle, liver, kidney, and lung (Sinha et al. 1999; Vassar et al. 1999 ) Ab peptides have also been detected in skin, subcutaneous tissue, and intestine (Joachim et al. 1989) as well as in muscle (Kuo et al. 2000b) . Although the formation of Ab species may be higher in the brain compared to other organs, it is possible that production of Ab in large peripheral organs such as skeletal muscles which comprises approximately 25% of the body weight in humans may result in a significant contribution to the plasma Ab pool (Kuo et al. 2000b) . Platelets are another source of Ab, albeit mostly Ab40 (Bush et al. 1990; Chen et al. 1995; Evin et al. 2003) . Detection of lower Ab levels (1:2) in the ventricular CSF samples compared to the spinal CSF samples also suggest contribution of Ab from periphery (de Leon et al. 2004) .
Another factor that may confound the detection of Ab is the transporter-dependent movement of Ab into and from the brain. Animal data suggest that approximately 10% of Ab from the brain interstitial fluid (ISF) moves into blood stream via ISF bulk flow (Shibata et al. 2000) . However, most of the movement of Ab is thought to be dependent on transporters such as low-density lipoprotein receptor-related protein-1 (LRP-1) (Deane et al. 2004; Shibata et al. 2000) and receptor for advanced glycation end products (RAGE) (Deane et al. 2003) due to the presence of tight endothelial cell junctions at the blood-brain barrier (BBB) (Begley and Brightman 2003) . Taken together, these reasons may explain the difficulty in establishing a direct correlation between plasma Ab and CSF Ab levels ( Vanderstichele et al. 2000; Mehta et al. 2001; Giedraitis et al. 2007; Matsumoto et al. 2007) . Further, these factors may explain why plasma Ab levels do not correlate well with brain Ab levels at autopsy (Freeman et al. 2007 ) or in vivo imaging by PIB compound (Fagan et al. 2006) in AD cases.
One interesting finding observed in several of these studies is the effect of aging on plasma Ab levels in humans (Matsubara et al. 1999; Mayeux et al. 1999 Mayeux et al. , 2003 Fukumoto et al. 2003; Ertekin-Taner et al. 2008; Sundelof et al. 2008 ). Specifically, increase in age alone correlated with increase in plasma Ab levels in some studies. This was demonstrated in cognitively normal adults (Matsubara et al. 1999) as well as in sAD/MCI and other neurological controls (Fukumoto et al. 2003) . This increase may be due to aging related changes. Tamaki et al. demonstrated decreased levels of hepatic LRP-1 with concomitant decrease in hepatic Ab40 uptake in aged versus young rats (Tamaki et al. 2006) . If the same holds true for humans, decreased peripheral uptake and clearance of Ab in the liver may be contributing to the increase in plasma Ab levels in older adults.
The effects of aging also complicate the interpretation of plasma Ab levels. It is possible that the gradual decrease in plasma Ab levels in the AD group may eventually fall to the same range as the normal controls whose plasma Ab levels increase in an age-dependent manner (Golde et al. 2000) . This may explain why much of the plasma Ab data in cross-sectional studies do not show significant differences between sAD and controls. The longitudinal studies seem more promising, with some studies showing initially elevated Ab42 levels in those that eventually develop AD (Mayeux et al. 1999 (Mayeux et al. , 2003 . Most show that subjects who manifest sAD within the time frame of the study start with Scheuner et al. (1996) N o N o Tamaoka et al. (1996) N o N o Kosaka et al. (1997) N o N o Iwatsubo (1998) Studies that investigated subjects with mild cognitive impairment (MCI) and cognitively normal subjects who were followed longitudinally were also included. Plasma Ab did not vary with cognitive scores (Fukumoto et al. 2003; Mehta et al. 2000; Pesaresi et al. 2006) , ApoE status (Fukumoto et al. 2003; Mayeux et al. 1999 Mayeux et al. , 2003 Pesaresi et al. 2006; Vanderstichele et al. 2000) , or education (Mayeux et al. 1999 The levels of plasma Ab40 were significantly higher in the AD group than the controls (P = 0.005), however, these measurements were stated to be not useful as a diagnostic tool due to a considerable overlap between the two groups c Overall comparison of the plasma Ab42 levels between the MCI group and age matched controls did not show a significant difference. Subgroup analysis based on gender showed significantly higher Ab42 levels in female MCI subjects as compared to female controls (P \ 0.05) d This study reported similar association between plasma Ab levels and dementia and between plasma Ab levels and its subtype Alzheimer's disease. Lower Ab42/40 ratio was associated with increased risk for dementia e There was no plasma Ab40 levels reported in this study. A subset of patients were followed for 18 months f This study reported a higher Ab 42, 40 and 42/40 at baseline in subjects who subsequently developed AD compared to controls; however, baseline Ab42 and higher Ab42/Ab40 ratio levels were associated with increased risk of AD g This study reported a lower Ab42/40 at baseline in subjects who subsequently developed AD compared to controls. Lower Ab42/40 ratio was associated with increased risk for MCI/AD h This effect was shown in elderly men (77 years old at baseline), but not in younger men (70 years old at baseline)
higher plasma Ab42 levels, and the Ab42/Ab40 ratios also appear to be significantly different from those who remain asymptomatic, albeit different patterns that have been observed in different studies (Table 1) (Mayeux et al. 1999; Graff-Radford et al. 2007 ). It may also be important to understand the genetics of sAD in order to correctly interpret plasma Ab levels, as plasma Ab42 was shown to be elevated in the extended family members of some of the subjects with sAD or LOAD (Ertekin-Taner et al. 2001 . Recently, different studies have investigated the timedependent variability of Ab levels in CSF. One study has shown that CSF Ab levels are thought to have significant variability (1.5-to 4-fold) over 12-36 h, and that they may be dependent on the time of day or activity (Bateman et al. 2007) , while other studies have shown that they are stable up to an average of 10-18 months of follow up (Kanai et al. 1998; Andreasen et al. 1999) . Plasma Ab surprisingly has less variability, with remarkable reproducibility over a 3-day period in 19 subjects. There was a small but significant difference in the levels measured in the morning versus afternoon. There was also a good reproducibility in 32 subjects from a different cohort over a 12-week period (Ertekin-Taner et al. 2008) .
Taken together, the interpretation of the cross-sectional studies may be complicated by the complex nature of plasma Ab, whereas longitudinal studies of plasma Ab may be a better indicator of disease progression. Further investigations are necessary to understand Ab production and clearance, and may lead to a better understanding of the diagnostic potential of plasma Ab.
Mouse
In addition to endogenous mouse APP expression, transgenic mice overexpress human APP under the regulation of a specific promoter element. Endogenous mouse APP is found primarily in the brain and lung with lower levels of expression in the spleen, stomach, large intestine, and skin (Kawarabayashi et al. 2001) . The promoter that drives the transgene dictates the expression of human APP in mouse models of AD, hence, this expression is highly model specific. For example, in Tg2576 mice human APP is expressed at high levels in brain, spleen and lung, with lower levels of transgene expression in skin, bone, muscle, heart, pancreas, stomach, and large intestine (Kawarabayashi et al. 2001) . BACE1 expression, which is necessary for the formation of Ab42, is limited to the brain of wild-type mice by Western blot analysis (Laird et al. 2005) . By sensitive ELISA measurements, Ab has been detected at low levels in peripheral organs (10-24 pmol/g), whereas the levels in the brain were 20-to 40-fold higher in Tg2576 mice (Kawarabayashi et al. 2001) . Therefore, the expression patterns of human APP and mouse BACE1 are likely to affect the availability of Ab in plasma, and should be considered when interpreting the plasma Ab data from mouse models of AD.
Similar to the data in humans, plasma Ab levels in AD mouse models are conflicting. Using the Tg2576 mouse model, Kawarabayashi et al. have shown that the plasma levels of Ab are inversely related to Ab plaque burden (Kawarabayashi et al. 2001 ). As mentioned above, Ab formation in this model is high in the brain, but also present in peripheral organs (Kawarabayashi et al. 2001) . As total brain levels of Ab increased, indicating increasing plaque formation, CSF and plasma levels of Ab concurrently decreased. This was not the case in wild-type mice, and therefore could not be attributed to normal aging (Kawarabayashi et al. 2001) .
Ab levels in plasma and CSF in the PDAPP mouse model of AD do not correspond with the findings in Tg2576 mice. In these mice, human APP expression is found only in the brain by Western blotting (DeMattos et al. 2001) . DeMattos et al. have reported a statistically significant positive correlation between CSF and plasma Ab levels in young mice prior to the onset of amyloid deposition. However, a robust correlation between CSF and plasma Ab was absent in older mice that were just beginning to accumulate amyloid plaques. If the older mouse cohort was divided into subsets by presence of amyloid plaques, the ratio of CSF to plasma Ab was found to be twice as high in mice with amyloid plaques compared to mice without amyloid plaques. Unlike the observations by Kawarabayashi et al., this increase was attributed to higher CSF Ab levels in the mice with amyloid plaques. Furthermore, the plasma Ab levels did not correlate with the amyloid burden in the brain (DeMattos et al. 2002b ). Hence, neither the levels of plasma Ab alone or the ratio of CSF:plasma Ab provided a clear cut prediction of amyloid formation in these mice.
Hence, the cross-sectional studies using mouse models of AD indicate that different models yield varying results, and corroborate the human data outlined in the previous section suggesting that such studies may not yield a reliable biomarker of early AD.
Challenges in Measuring Plasma Ab
A factor that may contribute to the inconsistent data on plasma Ab levels in both humans and transgenic mouse models of AD could be the difficulty in measuring Ab by traditional ELISA assays. APP and other soluble APP fragments in biological samples may compete with Ab peptides for capture and detection antibody in an ELISA assay (Golde et al. 2000) . It has been shown that 6E10, a common antibody used in Ab-specific ELISA assays, binds full-length APP, which could potentially interfere with the ability of 6E10 to sensitively detect Ab species in plasma (Englund et al. 2007 ). Englund et al. have also demonstrated that an elevated level of Ab protofibrils formed during the Ab aggregation process leads to a reduced signal by traditional sandwich ELISA (Englund et al. 2007 ). Since oligomeric Ab species are poorly detected by Ab ELISA assays, only a subset of Ab species present in the biological samples are accurately measured, leading to a potential underestimation of total Ab levels (Stenh et al. 2005) . Furthermore, presence of N-terminally truncated Ab species in AD brains may create some problems for ELISA assays with N-terminal capture antibodies (Naslund et al. 1994; Ida et al. 1996) .
Ab binding proteins in the plasma also pose problems in measuring Ab levels. Proteins such as albumin (Biere et al. 1996) , a2 macroglobulin , various lipoproteins (Koudinov et al. 1994; Biere et al. 1996) , and others ) are known to bind Ab. Some studies have shown that large quantities of Ab may remain ''sequestered'' by binding proteins, and interfere with ELISA quantification (Kuo et al. 2000a; Slemmon et al. 2007 ). This ''masking'' effect by the plasma binding proteins ) may also strengthen the case for longitudinal studies rather than cross-sectional studies. There is probably less variability in binding protein compositions within a subject than between subjects, as long as there has not been a major change in health that may affect binding proteins levels such as albumin.
Different steps in blood sample processing can also lead to underestimation of Ab levels in plasma. Processing of the whole blood to plasma would spin down the platelets which are known to contribute to the blood Ab pool (Bush et al. 1990; Chen et al. 1995; Evin et al. 2003) . However, one study has demonstrated that over 90% of the Ab appears to remain within the plasma component when compared to the Ab levels in the whole blood prior to processing (Slemmon et al. 2007 ). Other steps in the sample processing that influence plasma Ab detection has been reviewed previously (Vanderstichele et al. 2000) .
Antibody-Modulated Plasma Ab Levels
Although the utility of plasma Ab as a biomarker for AD is difficult to interpret, the data collected from CSF samples appear to be more consistent. The inherent challenges in measuring plasma Ab may further limit the potential of this strategy. However, it has been proposed that the equilibrium of Ab can be disturbed by the administration of an Ab-binding agent, such as an Ab-specific antibody, in the blood. By binding Ab in the blood, the antibody can potentially sequester plasma Ab, shifting the equilibrium of soluble Ab species, and causing a net efflux of Ab from the brain to the plasma (Fig. 1) (DeMattos et al. 2001 (DeMattos et al. , 2002a ). This hypothesis is designated the ''peripheral sink mechanism' ' (DeMattos et al. 2001) . Such an approach could maximize the levels of Ab available for detection in the plasma. In the following paragraphs, we will outline the data in support for using Ab-specific antibodies to detect plasma Ab.
Human
Following antibody-mediated amelioration of Ab deposition and behavioral deficits after Ab vaccinations in tg mouse models of AD (Janus et al. 2000; Morgan et al. 2000) , Dodel et al. examined whether naturally occurring human antibodies which recognizes Ab can be used for treatment of AD. The first study involving 7 subjects with neurological disorders receiving intravenous immunoglobulin (IVIG) demonstrated that there was a significant reduction in the CSF Ab levels accompanied by a significant increase in serum Ab (Dodel et al. 2002) . In another study involving 5 AD patients, infusion of IVIG again resulted in decrease in CSF Ab with increase in serum Ab (Dodel et al. 2004 ). This was similar to the observations in Fig. 1 Amyloid-beta (Ab) 1-40 and 1-42 are synthesized in the brain (Laird et al. 2005) (1), as well as in the periphery (Irizarry et al. 1997; Joachim et al. 1989; Vassar et al. 1999 ) (2). Circulating Ab peptides enter the blood stream (3) and are partly cleared by the LRP-1 receptors in the liver (Tamaki et al. 2006 ) (4). Soluble extracellular brain Ab (5) may accumulate in the brain parenchyma as amyloid plaques. Receptor mediated movement of the soluble Ab through the blood-brain barrier (BBB) (6) is mediated by transporters such as low-density lipoprotein receptor-related protein-1 (LRP-1) (Deane et al. 2004; Shibata et al. 2000) for efflux, and receptor for advanced glycation end products (RAGE) (Deane et al. 2003) for influx. Once in the blood, Ab peptides are bound by numerous binding proteins such as ApoE (Tanzi et al. 2004) , albumin (Biere et al. 1996) , and others (7). Ab-specific IgG is also able to bind Ab peptide in the blood, and may induce efflux of Ab from the brain to the blood via the ''peripheral sink'' mechanism (DeMattos et al. 2001) the tg mouse models of AD (see below), but more studies will need to be conducted to determine whether the Ab levels after IVIG can be used as a biomarker. In active immunization trials, generation of antibodies against Ab was not associated with changes in CSF or plasma Ab levels (Hock et al. 2003) .
Mouse
In 2001, DeMattos et al. demonstrated that administration of an antibody against the mid-region of Ab (m266) was able to induce a rapid increase of Ab total:IgG complex from 150 pg/ml basal level to at least 15,000 pg/ml 6 h after i.v. antibody administration in young PDAPP mice prior to plaque onset (DeMattos et al. 2001 ). This group has previously shown that the unmodified plasma Ab40 levels in PDAPP mice do not correlate with brain amyloid plaque burden (DeMattos et al. 2002b) , in concordance with the human studies outlined above. However, administration of the m266 antibody in this mouse model induced an efflux of Ab40 from the central nervous system (CNS) into the plasma that correlated with the brain amyloid plaque load (DeMattos et al. 2002a ). The m266 antibody has also been utilized to demonstrate a dose-dependent increase in plasma Ab40 levels in PDAPP transgenic mice following i.p. injections, which was accompanied by cognitive improvement, suggesting that antibody injection may also have therapeutic benefits (Dodart et al. 2002) .
Levites et al. have further characterized the effect of Ab antibody injection in young Tg2576 mice prior to the onset of amyloid plaque deposition. This group demonstrates a 25-fold increase in plasma levels of Ab42 within 1 day following intraperitoneal (i.p.) administration of 500 lg Ab9 (a mouse monoclonal antibody with epitope within Ab1-16). Furthermore, an Ab9:Ab40 complex with a halflife of approximately 7 days is detected in the plasma. Preclearing the plasma with a protein A/G, which removes mouse IgG, abolished greater than 90% of the plasma Ab ELISA signal. This data suggests that the majority of Ab that is detected in plasma is bound to the injected antibody, and that the Ab:antibody complex is not a classic immune complex subject to rapid clearance (Levites et al. 2006 ). This supports the idea that the administration of Ab antibody in mouse models of AD may be a feasible approach to maximize the measurable levels of Ab in the plasma.
In support of using a peripheral sink mechanism to enhance the detection of Ab in blood, a number of studies have demonstrated enhanced levels of Ab total, Ab40 and/ or Ab42 after Ab antibody administration (Table 2 ) (Lemere et al. 2003; Asami-Odaka et al. 2005; Hartman et al. 2005; DaSilva et al. 2006; Gray et al. 2007; Takata et al. 2007 ). However, the increases in Ab after Ab antibody administration vary from 2-fold to approximately 1,000-fold (Table 2) , and in some cases there is no significant difference between antibody-induced Ab levels and controls (Seabrook et al. 2006; Zamora et al. 2006) . There is also considerable divergence in the plasma Ab levels reported in two separate studies that employed the same antibody (m266) and the same mouse model (Table 2) (DeMattos et al. 2001; Dodart et al. 2002) . Patients at risk for AD may exhibit very mild elevations in soluble Ab levels as compared to healthy controls, therefore it is possible that very large inductions in plasma Ab are necessary to identify the at-risk population. This potential caveat needs to be further examined in order to ascertain the feasibility of antibody-induced Ab levels as a diagnostic biomarker.
Furthermore, the increases in plasma Ab levels are compared to different types of controls in the above-mentioned studies, including pre-injection Ab levels (DeMattos et al. 2001; Gray et al. 2007; Takata et al. 2007 ), Ab levels in transgenic mice given vehicle (Dodart et al. 2002; Asami-Odaka et al. 2005; DaSilva et al. 2006; Seabrook et al. 2006; Zamora et al. 2006) , and Ab immunized wild-type mice (Lemere et al. 2003) . All humans produce Ab, but it is possible that people at risk for AD have a higher production of Ab compared to normal controls. Similarly, non-transgenic mice produce endogenous mouse Ab at lower levels than the human Ab that is produced in transgenic AD mouse models. Therefore, non-transgenic mice, or mice producing human Ab at a lower level, could serve as an appropriate control for studies testing the efficacy of agents that induce Ab efflux from the brain to the blood, yet these types of controls are not always included.
Instead, the increases in Ab are commonly compared to ''baseline'' Ab readings, which does not provide much information regarding if the Ab elevations in patients at risk for AD would be distinguishable from those of a healthy individual. In addition, the range of controls used in these animal studies may account for some of the variability in plasma Ab increases. The variations in fold-Ab elevations may also be attributable to the Ab antibodies, tg mouse models, injection routes, and detection systems used.
Moreover, plasma Ab levels may change with age due to changes in clearance of the Ab peptide (Tamaki et al. 2006) . Hence, it will be important to determine the ability of Ab antibodies to induce elevations in young transgenic mice that have not yet developed amyloid plaques, as it is crucial that AD can be detected prior to the onset of symptoms. This has been tested in one mouse model where Ab levels were elevated by approximately 500% in preplaque mice and 250% in mice that had developed amyloid plaques (Takata et al. 2007 ). However, the dose of antibody administered in this study differed for the two age groups, making it difficult to directly compare the effectiveness of Ab antibody to induce Ab efflux from the brain at different ages (Table 2) (Takata et al. 2007) .
In order to optimize antibody-induced increases in Ab levels for a diagnostic test, the most suitable antibody (isotype, affinity, and epitope), injection route, kinetics and detection system must be determined. As will be discussed in the following paragraph, the detection of antibodyinduced Ab levels has its own set of inherent challenges.
Challenges in Measuring Antibody-Induced Plasma Ab
Measurements of antibody-induced plasma Ab levels may be confounded by the presence of a third antibody in the traditional sandwich ELISA design. In addition to the capture antibody (coating the ELISA plate) and the detection antibody (which detects the antigen bound to the capture antibody), the plasma Ab that is measured in this assay may be complexed with the injected antibody used to sequester Ab in the periphery. Ab42 is a small peptide and many of the Ab antibody epitopes overlap, potentially leading to steric hindrance in detection assays such as ELISAs. Gray et al. have shown that ELISA measurements of Ab in plasma using 1A10 as the capture antibody are abrogated if the plasma sample is spiked with antibody 1A10. However, ELISA readings can be restored to near 100% if the plasma is treated with 2% SDS before dilution and addition to the ELISA plate ). Further, as mentioned previously, oligomeric species of Ab are poorly detected by ELISA assays (Englund et al. 2007 ), a complication that is likely to persist when antibodyinduced Ab levels are measured.
Other Modifiers of Plasma Ab/Ab binding Agents
Human
Similar to AD, insulin resistance syndrome is also prevalent in the US, and is associated with aging (Harris et al. 1998) . Insulin receptors are present throughout peripheral tissues as well as in the brain (Schulingkamp et al. 2000) . There are in vitro data suggesting that insulin increases extracellular Ab by reducing insulin degrading enzyme (IDE)-mediated Ab degradation (Qiu et al. 1998) . In addition to competing with Ab for IDE, insulin facilitates trans-Golgi network (TGN) transport of Ab, and increases Ab secretion (Gasparini et al. 2001) . Hence, systemic insulin levels may affect the levels of plasma Ab. In humans, age-dependent increases in CSF Ab42 levels were observed in cognitively normal subjects who received continuous insulin infusions compared to those who received saline infusions (Watson et al. 2003) . Plasma Ab42 levels were also increased in the insulin infusion group compared to the saline infusion group, and this increase in Ab42 levels correlated with higher BMI values (Fishel et al. 2005) . In another study, insulin infusion was able to induce greater percentage increases in plasma Ab levels in AD patients, with no overall change in cognitively normal controls (Kulstad et al. 2006) . AD patients of different ApoE genotypes may have different dose-response pattern to insulin infusion as assessed by cognitive tests as well as plasma APP levels (Craft et al. 2003 ). In addition to the possible mechanisms of plasma Ab increases mentioned above, there may be other explanations for these observations (Kulstad et al. 2006) . Insulin may act by activating insulin receptors present in the platelets and release Ab via insulin signaling molecule phosphatidylinositol 3-kinase (PI3K) (Nystrom and Quon 1999; Skovronsky et al. 2001) . Insulin may also mediate plasma Ab levels via LRP-1 mediated clearance of Ab40 as seen in rats (Tamaki et al. 2007) , as well as by reducing the plasma level of APP in humans (Boyt et al. 2000) . Finally, the observed increase in plasma Ab may be secondary to enhanced efflux of Ab from the brain, as can be inferred from insulin-induced increases in Ab levels in the CSF (Watson et al. 2003) . Therefore, insulin infusion appears as a potential tool in modulating plasma Ab levels.
Mouse
Due to the concerns about the inflammatory effects of antibody injection (Robinson et al. 2003) , other compounds that have Ab binding capacity without immunomodulative effects have been explored in mice. Both gelsolin (Chauhan et al. 1999 ) and ganglioside G M1 (Choo-Smith et al. 1997) bind Ab with high affinity, and gelsolin also co-immunoprecipitates with Ab in human plasma (Chauhan et al. 1999) . Additionally, only 1% of gelsolin can cross the blood-brain barrier (Saulino and Schengrund 1994) and G M1 is a large compound (86 kDa) unlikely to readily enter the CNS, indicating that these compounds may be well suited for maximizing plasma levels of Ab. When these agents were administered to PS/APP tg mice by intraperitoneal injection by Matsouka and colleagues, G M1 induced an approximate twofold increase of plasma Ab40 that was statistically significant. Three weeks after the initial G M1 administration, plasma Ab42 levels were also nearly twofold higher than those of vehicle treated animals. However, intraperitoneal injection of gelsolin did not alter plasma Ab levels. Both compounds reduced brain Ab burden, and because of their low availability to the CNS, this suggests that these compounds are acting via peripheral sink mechanisms (Matsuoka et al. 2003) .
Another agent known to bind amyloid is the histological dye Congo red. While Congo red readily the stains b-pleated sheet conformations of amyloid plaques, it has been reported to be a poor stain of diffuse amyloid deposits (Braak et al. 1989; Klunk et al. 1989 ). However, recent evidence of Congo red analogs with affinity for soluble oligomeric Ab species has emerged (Maezawa et al. 2008) . Intravenous administration of the Congo red derivative Chrysamine G results in a rapid and statistically significant increase in plasma Ab40 levels, but this increase is minimal (125% of pretreatment) (Matsuoka et al. 2005) . Other Congo red derivates tested in the study did not induce an increase in plasma Ab levels (Matsuoka et al. 2005) .
As mentioned previously, LRP-1 is a receptor which mediates transport of Ab across the BBB, as well as clearance of systemic Ab by the liver (Quinn et al. 1997; Shibata et al. 2000; Deane et al. 2004 ). LRP-1 binds Ab with high affinity, and this binding is mediated by two domains known as cluster II and cluster IV (Deane et al. 2004) . LRP-1 also has a higher affinity for Ab than other LRP-1 ligands such as ApoE4 (Sagare et al. 2007) , and soluble LRP is found in human plasma (Quinn et al. 1997) , making it an ideal candidate for sequestration of Ab in the plasma. Sagare et al. have utilized a soluble recombinant LRP fragment that encompasses cluster IV (LRP-IV) to induce peripheral sink activity in mice (Sagare et al. 2007) . Intravenous administration of LRP-IV in wild-type C57BL/ 6 mice for 5 days resulted in a statistically significant twofold approximate increase in endogenous mouse Ab40, and 1.5-fold increase in endogenous mouse Ab42, as compared to vehicle injected mice. Similarly, statistically significant twofold increases in plasma Ab40 and Ab42 were observed in Tg2576 transgenic mice after daily i.p. injection of LRP-IV for 3 months, compared to vehicle. The plasma Ab was primarily associated with LRP-IV, but LRP-IV was not found in the CSF and was not taken up by the brain (Sagare et al. 2007 ). This data suggests that LRP-IV may induce sequestration of plasma Ab by a peripheral sink mechanism.
Finally, the Nogo-66 receptor (NgR) limits axonal growth in the human brain and also interacts with the central domain of Ab (Park et al. 2006a, b) . When NgR was administered subcutaneously over a period of 3 months in the APP/PS1 mouse model of AD, there was no significant difference in the absolute Ab plasma levels of NgR treated animals compared to controls. However, treatment was accompanied by reductions in brain Ab levels, improvement in cognitive performance, and a significant twofold increase in the ratio of plasma/brain Ab42 (Park et al. 2006b ). This data provides some evidence that plasma Ab binding agents administered in circulation could create an efflux of Ab from brain to blood.
While peripheral sequestration of Ab by injection of agents with high affinity for Ab appears to be a feasible approach to increase plasma Ab levels, the agents tested to date have not yielded substantial increases in plasma Ab as compared to vehicle. As mentioned above, considerable elevations in plasma Ab may be necessary to differentiate individuals in the early stages of AD from healthy controls. Furthermore, in the studies mentioned above, the plasma Ab levels after administration of the Ab-binding agent have been compared either to pre-treatment plasma Ab levels or to Ab levels from vehicle treated transgenic animals. As demonstrated by Sagare et al., at least one of these Ab binding agents, LRP-IV, is able to provoke increases in endogenous mouse Ab in wild-type mice, as well as increases in human Ab derived from transgene expression in Tg2576 mice (Sagare et al. 2007 ). All humans, whether they are at risk for AD or not, produce Ab. Similarly, both transgenic mice and non-transgenic mice produce some form of Ab, although the levels of Ab are considerably higher in transgenic mice. None of the studies above have compared the increases in plasma Ab levels induced by the Ab binding agent in transgenic mice versus non-transgenic mice. Although this scenario would not be an ideal representation of a diagnostic test in humans, it would be important to examine how these agents might allow differentiation of plasma samples from AD patients compared to healthy controls.
Also, a careful kinetics study to determine when the Ab levels peak after administration of the Ab-binding agents will be necessary since the clearance of these agents will likely vary. Finally, as is the case with antibody-induced plasma Ab levels, it is important that mice of different ages are tested with the Ab-binding agents. Studies using mice with pathology ranging pre-onset to significant amyloid plaque burden are necessary in order to determine if these agents could be useful as a preclinical diagnostic test.
Conclusion
On the basis of the data in humans and tg mouse models of AD, unmodified levels of plasma Ab alone do not appear to be reliable as a biomarker of AD at least in cross-sectional studies, while longitudinal studies seem more promising. Many modulators of plasma Ab that are under investigation in humans as well as in animal models at this time, including Ab antibodies, Ab binding agents and insulin. These may be important in optimizing the plasma Ab levels, and may improve the diagnostic potential of plasma Ab. Standardization in the processing of the plasma would be also important (Golde et al. 2000; Galasko 2005 ) for the reasons discussed in this review article. Currently there are efforts to standardize the laboratory processing of plasma biomarkers, such as in the biomarker core of the Alzheimer's Disease Neuroimaging Initiative (ADNI) (Mueller et al. 2005) . In addition, understanding of other factors such as location of Ab synthesis and clearance would also play an important part in interpretation of Ab as a biomarker.
Another possible approach to the utilization of Ab as a biomarker of AD is the combination of this measurement with other biomarkers in the plasma, CSF, or imaging studies. A combination of multiple biomarkers would be very informative in predicting the subjects who would go on to develop AD (Ray et al. 2007 ). Furthermore, as many therapeutic agents that specifically target Ab are under investigation at this time (Cummings et al. 2007) , there is need for a biomarker that can provide information on whether these agents have affected the levels of brain Ab (Galasko 2005) . The importance of plasma Ab remains as a non-invasive biomarker for monitoring the efficacy of these agents.
